Company Overview

Kraig Biocraft Laboratories, Inc. is a biotechnology company focused on the development and commercialization of genetically engineered spider silk fibers. The company operates at the intersection of biotechnology, advanced materials, and textiles, with the objective of producing high-performance, sustainable fibers that replicate or enhance the properties of natural spider silk. Its core technology centers on recombinant DNA and transgenic silkworms designed to produce spider silk proteins at commercial scale.

The company’s primary business line is the production and future sale of spider silk-based fibers and yarns for use in technical textiles, performance apparel, defense applications, and industrial materials. Kraig Biocraft Laboratories positions itself as one of the few companies pursuing scalable spider silk production using silkworm-based systems, which it presents as a potential cost and scalability advantage over microbial fermentation approaches. Founded in 2006, the company has evolved from early-stage research into pilot-scale production, with an emphasis on moving toward commercial manufacturing through overseas partnerships.

Business Operations

Kraig Biocraft Laboratories conducts its operations through internally developed transgenic silkworm strains and proprietary spider silk protein constructs. The company’s activities include genetic research and development, silkworm breeding, fiber production, and material testing. Revenue to date has been minimal, and the company remains primarily in a development and pre-commercialization phase, with operations funded largely through equity financing rather than product sales.

Operationally, Kraig Biocraft Laboratories relies on a combination of U.S.-based research management and international production relationships. The company has disclosed long-standing production arrangements in Asia, particularly in Vietnam, where silkworm rearing and cocoon production are conducted through contracted facilities rather than wholly owned manufacturing plants. The company does not report significant owned physical manufacturing assets and instead emphasizes intellectual property, genetic strains, and production know-how as its core assets.

Strategic Position & Investments

The company’s strategic direction is centered on achieving consistent, repeatable commercial-scale production of spider silk fibers and securing downstream partners in textiles, defense, and advanced materials. Growth initiatives have focused on refining silkworm strains, improving yield and fiber consistency, and validating material performance for end-use applications. Kraig Biocraft Laboratories has publicly highlighted interest in defense-related materials, including lightweight and high-strength fibers, though no large-scale procurement contracts have been confirmed in public filings.

Kraig Biocraft Laboratories has not completed major acquisitions of operating companies and does not maintain a diversified investment portfolio. Instead, its investment strategy has been concentrated on internal research and development and incremental expansion of production capacity through external partners. The company has reported collaboration discussions with textile and material companies, but publicly verified long-term commercial supply agreements remain limited based on available disclosures.

Geographic Footprint

The company is headquartered in the United States, where executive management, corporate governance, and strategic planning are based. Research oversight and intellectual property management are also conducted domestically. Kraig Biocraft Laboratories’ international footprint is primarily operational rather than corporate, reflecting its reliance on overseas sericulture infrastructure.

The most significant international presence is in Southeast Asia, particularly Vietnam, which serves as the company’s primary production region for transgenic silkworms and cocoon harvesting. This geographic approach reflects the historical concentration of global silk production in Asia and provides access to established expertise, labor, and climate conditions favorable to silkworm cultivation.

Leadership & Governance

Kraig Biocraft Laboratories was founded by Kim K. Thompson, who has played a central role in shaping the company’s long-term vision around commercializing spider silk through biotechnology. The leadership team emphasizes persistence in long-cycle biotechnology development and positions the company as a platform innovator rather than a near-term revenue generator.

Key executives and leaders include:

• Kim K. Thompson – Founder, Chief Executive Officer
• Jon Rice – Chief Operating Officer
• Ken Mills – Chief Financial Officer
• Gilbert Gonzalez – Director of Research and Development

The company is governed by a board of directors typical of a publicly traded micro-cap biotechnology firm, with oversight focused on capital management, regulatory compliance, and intellectual property protection. Leadership communications consistently emphasize technological differentiation, long-term value creation, and the strategic importance of achieving scalable production milestones before broad commercial rollout.